<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04654741</url>
  </required_header>
  <id_info>
    <org_study_id>4/2018</org_study_id>
    <nct_id>NCT04654741</nct_id>
  </id_info>
  <brief_title>The Rate of Embryo Euploidy in Progestin-primed Ovarian Stimulation Cycles</brief_title>
  <acronym>PPOS</acronym>
  <official_title>The Rate of Embryo Euploidy in Women Treated With Progestin-primed Ovarian Stimulation Versus Conventional Ovarian Stimulation: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Casa di Cura Privata Villa Mafalda</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Casa di Cura Privata Villa Mafalda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this non-inferiority randomized controlled trial is to assess the rate&#xD;
      of blastocyst euploidy and the number of euploid blastocysts in women undergoing IVF/ICSI and&#xD;
      treated with PPOS versus conventional ovarian stimulation based on the use of GnRH antagonist&#xD;
      The hypothesis is that PPOS is associated with a rate of blastocyst euploidy similar to what&#xD;
      found with the conventional ovarian stimulation. In other words, the number of euploid&#xD;
      blastocysts that can be obtained with the PPOS strategy is expected to be the same obtained&#xD;
      with conventional ovarian stimulation.&#xD;
&#xD;
      Moreover we expect to find non significant differences in all intermediate outcome of the IVF&#xD;
      cycles, such as in the rate of premature LH surge, in the rate of patients with elevation of&#xD;
      Progesterone on the triggering day, in FSH consumption and length of stimulation, in the rate&#xD;
      of poor response and hyperresponse, in number of retrieved and mature oocytes, in&#xD;
      fertilization and blastulation rate, in the number of available blastocysts and in the&#xD;
      morphological quality of blastocysts&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study proposed is a non-inferiority randomized controlled trial Only patients undergoing&#xD;
      PGT-A could be included. PGT-A will be proposed to couples for reasons of advanced maternal&#xD;
      age, recurrent miscarriage, repeated implantation failure, or severe male infertility, as&#xD;
      well as to all good-prognosis patients who desire information regarding the health status of&#xD;
      their embryos.&#xD;
&#xD;
      396 patients will be included in this study (198 per arm). After randomization, patients will&#xD;
      be treated according to the PPOS or conventional ovarian stimulation strategy. For all&#xD;
      patients the ICSI and PGT-A will be applied and the intermediate and definitive outcomes of&#xD;
      the ART cycles will be recorded.&#xD;
&#xD;
      Ovarian Stimulation Controlled ovarian stimulation will start on the second day of the&#xD;
      menstrual cycle, with an initial dose of recombinant follicle stimulating hormone (rFSH)&#xD;
      (chosen according to age, antral follicle count or serum AMH and body mass index,BMI) In&#xD;
      addition to the gonadotrophin, participants will receive progestins (MPA) in the PPOS or GnRH&#xD;
      antagonists in the conventional ovarian stimulation. Ovarian stimulation will culminate with&#xD;
      the oocyte retrieval procedure.&#xD;
&#xD;
      Oocyte Insemination, Embryo Culture, and Biopsy. All biologic procedures will be performed as&#xD;
      already described. Only oocytes with the first polar body extruded (metaphase II) will be&#xD;
      treated with the use of ICSI immediately after the denudation procedure. Finally, injected&#xD;
      oocytes will be moved to single drops of cleavage medium. Depending on the embryo's&#xD;
      development, the blastocyst stage can be reached on day 5, 6, or 7. On the day of biopsy,&#xD;
      5-10 trophectoderm cells will be gently aspirated into the biopsy pipette followed by a&#xD;
      laser-assisted removal from the rest of the blastocyst. Briefly, trophectoderm cell samples&#xD;
      and negative controls will be processed according to the Illumina protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blastocyst euploidy</measure>
    <time_frame>From the date of randomization up to the assessment of blastocyst euploidy (up to 20 weeks)</time_frame>
    <description>the rate of blastocyst euploidy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>premature lh surge</measure>
    <time_frame>From the date of randomization up to the completion of ovarian stimulation (up to 20 weeks)</time_frame>
    <description>the rate of premature lh surge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oocytes</measure>
    <time_frame>From the date of randomization up to the completion of ovarian stimulation (up to 20 weeks)</time_frame>
    <description>number of total and mature oocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blastocysts</measure>
    <time_frame>From the date of randomization up to the completion of the IVF cycle (up to 20 weeks)</time_frame>
    <description>number of total and good quality blastocysts</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">396</enrollment>
  <condition>IVF</condition>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Progestin Primed ovarian stimulation Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>progestin 10 mg daily during ovarian stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GnRH antagonist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GnRH antagonist 0.25 mg daily during ovarian stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medroxyprogesterone Acetate</intervention_name>
    <description>1 pill per day</description>
    <arm_group_label>Progestin Primed ovarian stimulation Group</arm_group_label>
    <other_name>Farlutal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganirelix Acetate</intervention_name>
    <description>1 injection per day</description>
    <arm_group_label>GnRH antagonist</arm_group_label>
    <other_name>Orgalutran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  advanced maternal age,&#xD;
&#xD;
          -  recurrent miscarriage,&#xD;
&#xD;
          -  repeated implantation failure,&#xD;
&#xD;
          -  severe male infertility,&#xD;
&#xD;
          -  patients who desire information regarding the health status of their embryos.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ovarian cyst,&#xD;
&#xD;
          -  previous surgery,&#xD;
&#xD;
          -  abnormal karyotype,&#xD;
&#xD;
          -  genetic or systematic disease&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ermanno Greco</last_name>
    <phone>+39335304960</phone>
    <email>ergreco1@virgilio.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Villa Mafalda</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ermanno Greco, MD</last_name>
      <phone>+39335304960</phone>
      <email>ergreco1@virgilio.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 22, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PGT-A</keyword>
  <keyword>IVF</keyword>
  <keyword>ICSI</keyword>
  <keyword>Blastocyst</keyword>
  <keyword>GnRH antagonist</keyword>
  <keyword>Progestin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Ganirelix</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

